Plain-English translation of NCT06043674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called to treat Richter's Transformation, which is when chronic lymphocytic leukemia (a blood cancer) transforms into a more aggressive type called diffuse large B-cell lymphoma. The medication will be given either by itself or combined with other approved drugs. The goal is to see if the medication can help people with this serious condition and understand how safe it is.
Richter's Transformation is a dangerous complication of chronic lymphocytic leukemia with very few good treatment options. While the medication has shown promise in treating similar blood cancers, it has never been formally tested in patients with Richter's Transformation, so doctors need to study whether it actually works for this specific condition.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly for about 9 months to receive the medication by IV infusion, with some doses requiring hospitalization for observation. You'll have blood tests, urine tests, imaging scans (CT or PET), heart tests, and possibly bone marrow biopsies to check how you're responding. After treatment ends, you'll continue follow-up visits every 3-6 months for up to 10 years to make sure the medication is working and to watch for any side effects.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States